Skip to content
Bamboo Works
Search
Sign in / Register
  • Categories
    • IPO
    • Ecommerce
    • Finance
    • Social Media/Entertainment
    • Consumer
    • Education
    • Healthcare/biotech
    • New Energy
    • Infrastructure/Resources
  • Fast News
  • Focus Companies
    • 360 DigiTech
    • Atrenew
    • Beigene
    • Cango
    • Daqo New Energy
    • Huazhu
    • Pop Mart
    • Tuya
    • Yalla
    • Yum China
  • Expert Corner
  • Premium Content
  • About Us
    • Who We Are
    • Our Writers
    • Partner with us
    • Contact Us
    • Join us
  • Eng
  • 简中
  • 繁中
Menu
  • Categories
    • IPO
    • Ecommerce
    • Finance
    • Social Media/Entertainment
    • Consumer
    • Education
    • Healthcare/biotech
    • New Energy
    • Infrastructure/Resources
  • Fast News
  • Focus Companies
    • 360 DigiTech
    • Atrenew
    • Beigene
    • Cango
    • Daqo New Energy
    • Huazhu
    • Pop Mart
    • Tuya
    • Yalla
    • Yum China
  • Expert Corner
  • Premium Content
  • About Us
    • Who We Are
    • Our Writers
    • Partner with us
    • Contact Us
    • Join us

oncology

Xiaobai Maimai Eyes Cancer Treatment as E-Commerce Pivot Sputters

Former P2P lender’s stock soared up to tenfold after announcement of latest shift, but later gave up much of the gains Key Takeaways: Xiaobai Maimai, the former P2P lender known…
October 26, 2021

Undervalued Zai Lab on Licensing Binge to Boost Cancer Treatment Portfolio

With $860 million in new cash from a recent share sale, company seeks to accelerate approval and rollout of new cutting-edge treatments from abroad Key takeaways: Zai Lab’s revenue should…
May 14, 2021

CStone Finds Tonic in Steady Stream of Drug Approvals, Licensing Deals

Cancer drug specialist reported its first significant revenue in 2020, following a string of milestones capped by a $200 million investment from Pfizer Key takeaways: Strong upfront licensing fees helped…
April 30, 2021

Newly Confident Hutchmed Weans Itself from Partners, Prepares to Stand on Its Own

Oncological drug specialist backed by billionaire Li Ka-shing sells OTC business and raises $200 million, half from Baring Private Equity Asia Key Takeaways Hutchmed predicts revenue from its core oncology…
April 16, 2021

Recent Articles

October 26, 2021

Xiaobai Maimai Eyes Cancer Treatment as E-Commerce Pivot Sputters

May 14, 2021

Undervalued Zai Lab on Licensing Binge to Boost Cancer Treatment Portfolio

April 30, 2021

CStone Finds Tonic in Steady Stream of Drug Approvals, Licensing Deals

April 16, 2021

Newly Confident Hutchmed Weans Itself from Partners, Prepares to Stand on Its Own

Follow us

Facebook Twitter Linkedin Weixin Weibo File-alt

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

Bamboo Works offers a range of partnerships for corporate and other partners, including opportunities for sponsored content, article-writing services and a wide range of promotions.

About Us
Focus Companies
Fast News
Expert Corner
Premium Content
Facebook Twitter Linkedin Weixin Weibo File-alt

Categories

  • Social Media/Entertainment
  • Consumer
  • Ecommerce
  • Healthcare/biotech
  • New Energy
  • IPO
  • Infrastructure/Resources
  • Education
  • Finance

Newsletter

For all latest news, offers and special announcements.
Subscribe
Copyright © 2022 Bamboo Works. All rights reserved.